N4 Pharma Plc Stock price

Equities

ONZ

GB00BYW8QM32

Pharmaceuticals

Market Closed - London S.E. 12:35:24 2024-03-28 pm EDT 5-day change 1st Jan Change
0.65 GBX -3.70% Intraday chart for N4 Pharma Plc -10.34% -23.53%
Sales 2021 - Sales 2022 - Capitalization 4.32M 5.45M
Net income 2021 -1M -1.26M Net income 2022 -1M -1.26M EV / Sales 2021 -
Net cash position 2021 1.78M 2.25M Net cash position 2022 1.92M 2.42M EV / Sales 2022 -
P/E ratio 2021
-5.22 x
P/E ratio 2022
-3.35 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 87.14%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on N4 Pharma Plc

1 day+11.11%
1 week+15.38%
Current month+7.14%
1 month+7.14%
3 months-16.67%
6 months-25.00%
Current year-11.76%
More quotes
1 week
0.60
Extreme 0.6
0.75
1 month
0.60
Extreme 0.6
0.85
Current year
0.60
Extreme 0.6
1.50
1 year
0.60
Extreme 0.6
2.30
3 years
0.60
Extreme 0.6
10.43
5 years
0.60
Extreme 0.6
16.00
10 years
0.60
Extreme 0.6
35.70
More quotes
Managers TitleAgeSince
Founder 59 13-12-31
Chief Tech/Sci/R&D Officer - 17-04-30
Members of the board TitleAgeSince
Director/Board Member 46 20-07-13
Founder 59 13-12-31
Chairman - 19-05-19
More insiders
Date Price Change Volume
24-03-28 0.65 -3.70% 1,668,891
24-03-27 0.675 0.00% 580,163
24-03-26 0.675 0.00% 523,124
24-03-25 0.675 -5.46% 498,899
24-03-22 0.714 +9.85% 512,267

Delayed Quote London S.E., March 28, 2024 at 04:56 am EDT

More quotes
N4 Pharma Plc is a United Kingdom-based specialist pharmaceutical company. The Company is focused on developing a silica nanoparticle delivery system to improve the cellular delivery of cancer treatments and vaccines. The Company is engaged in the development and commercialization of medicines through its delivery system, Nuvec. Nuvec is a silica nanoparticle technology with a patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical Phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. The Company's wholly owned subsidiaries include N4 Pharma UK Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock N4 Pharma Plc - London S.E.